Efficacy of the Whole-Course Case Management Model on Compliance and Satisfaction of Breast Cancer Patients with Whole-Course Standardized Treatment. (24th June 2022)

• Record Type: Journal Article
• Authors: Jin, Lijun; Zhao, Yunyan; Wang, Peng; Zhu, Ran; Bai, Jie; Li, Jie; Jia, Xue; Wang, Zunyi
• Other Names: Wu Xueliang Academic Editor.
• Is Part Of: Journal of oncology. Volume 2022(2022)
• Publication Date: 2022-06-24
• Subjects: Oncology -- Research -- Periodicals; Tumors -- Periodicals; Neoplasms; Oncology -- Research; Tumors; Periodicals; Periodicals; 616.994
• DOI: 10.1155/2022/2003324
• Languages: English
• ISSNs: 1687-8450

Abstract

Abstract : Objective . To explore the influence of the whole-course case management model on the compliance and satisfaction of breast cancer patients with the whole-course standardized treatment. Methods . Eighty breast cancer patients admitted to our hospital between April 2020 and June 2021 were assigned to receive either conventional nursing (routine group, n = 40) or whole-process case management (experimental group, n = 40) according to different nursing methods. Outcome measures included self-rating anxiety scale (SAS) scores, self-rating depression scale (SDS) scores, adverse reactions, treatment compliance, and nursing satisfaction. Results . After nursing, the SAS and SDS scores of the experimental group were significantly lower than those of the routine group P < 0.05 . The whole case management mode was associated with a significantly lower incidence of adverse reactions versus routine nursing P < 0.05 . The whole case management resulted in higher compliance of patients versus routine nursing P < 0.05 . The experimental group had a significantly higher nursing satisfaction versus the routine group P < 0.05 . Conclusion . The whole-process case management mitigates patients' negative emotions, strengthens their treatment compliance, lowers the incidence of postoperative adverse reactions, and improves nursing satisfaction, which may provide a viable nursing alternative for patients with breast cancer.